Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Survival
Extended benefit for women after 5 years of tamoxifen therapy is observed with letrozole
February 16th, 2006
An extended benefit for women who were disease-free after 5 years of tamoxifen therapy is observed with letrozole. "Women who are diagnosed with early breast cancer remain at considerable risk of recurrence over the next several decades, even if their tumors were small and lymph nodes were negative, and despite receiving standard adjuvant therapy," researchers at Guy's Hospital in London stated. "A majority of breast cancers are hormone (estrogen) receptor-positive and amenable to endocrine therapy, and for those women five years of the selective estrogen receptor modulator tamoxifen is standard therapy. Longer treatment of node-negative patients with tamoxifen may...
Source: Women's Health Weekly (2006-02-16)
|
